Merck wins interim relief against Teva
The High Court in London has granted an interim injunction against Teva to stop it launching a generic version of efavirenz, even though Teva had done nothing more than get market authorisation
Judge Birss, sitting in the High Court, granted pharmaceutical companies Merck Sharp & Dohne and Bristol-Myers Squibb (BMS) interim relief based on their argument that Teva must be planning to launch at risk because it refused to say when it...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.